AFT Pharmaceuticals (NZE:AFT, ASX:AFP) expects to achieve record sales of more than AU$200 million in fiscal 2025, up from AU$56 million in fiscal 2015 and AU$106 million in fiscal 2020, according to a Monday filing with the Australian and New Zealand bourses.

The upbeat outlook comes despite sales disruptions seen in the first half. The pharmaceutical company said it targets to achieve AU$300 million turnover on a rolling annual basis by the end of 2027.

AFT Pharmaceuticals' Kiwi shares were up past 1% in recent Monday trade.